swisspartners’s G Medical Innovations Holdings Ltd. Ordinary Shares GMVD Stock Holding History

swisspartners’s Portfolio GMVD Stock Details GMVD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,857	Closed	-$40K	–	85
2022 Q3	$40K	Buy	+4,857	New	+$71.4K	0.04%	78

Other funds holding GMVD

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HWM

HighMark Wealth Management St. Paul, Minnesota $246M AUM 35.95% 1-Year Est. Return

Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return

swisspartners's GMVD Position: Q4 2022 in Review

swisspartners sold out of G Medical Innovations Holdings Ltd. Ordinary Shares (GMVD) in Q4 2022, closing a stake of 4,857 shares — an estimated $40K sold.

swisspartners first reported a position in GMVD in Q3 2022 and held it in 1 quarter. The position peaked at $40K in Q3 2022. 6 funds tracked by Wall St. Rank hold GMVD as of Q4 2022.

swisspartners reported no remaining G Medical Innovations Holdings Ltd. Ordinary Shares position as of Q4 2022 after selling out during the quarter.
swisspartners sold 4,857 G Medical Innovations Holdings Ltd. Ordinary Shares shares in Q4 2022, an estimated $40K.
swisspartners first reported a position in G Medical Innovations Holdings Ltd. Ordinary Shares in Q3 2022 and held it in 1 quarter.
swisspartners's G Medical Innovations Holdings Ltd. Ordinary Shares position peaked at $40K in Q3 2022.
6 funds tracked by Wall St. Rank held G Medical Innovations Holdings Ltd. Ordinary Shares as of Q4 2022.

Based on swisspartners's 13F filing for Q4 2022, filed 14 Feb 2023.